Last week, Cantor's Capital Introduction team hosted its inaugural Biotech Panel, moderated by Senior Managing Director and Senior Biotechnology Analyst, Eric Schmidt, Ph.D. Panelists shared their insights on the latest trends and future directions in biotechnology, discussing groundbreaking therapies, diagnostics, and innovative solutions driving the sector forward. A special thank you to our panelists for their invaluable contributions to the success of this event: Anna Cosslett Yaeger, Partner & Head of Public Equities of 5AM Ventures; Vincent Aita, CIO & Managing Partner of Cutter Capital Management, LP; Kevin Pyun, CIO of Dellora Investments; and Rod Wong, CIO & Managing Partner of RTW Investments, LP. If you missed the panel or are interested in learning more about Cantor Prime Services and our Capital Introduction capabilities, please reach out to us here: https://lnkd.in/eB6TnVmE.
Cantor Fitzgerald’s Post
More Relevant Posts
-
Are you attending RESI Boston next week? If so, join Portal and Radyus Research for a panel discussion with our Director of Lab and Scientific Operations, Krisha Panchalingam! This panel will discuss maximizing pre-clinical development success for VC-backed startups through CRO partnerships. Additional information is below, and we hope to see you there!
Join us at RESI Boston next week presented by Life Science Nation! Radyus Research CEO and co-founder, Dr. Marta New will be moderating a panel on September 18th at 3pm ET featuring Sean Evans Senior Associate, Venture Investments of Johnson & Johnson, Carrie Saulsbery CSO of IGM Biosciences, Inc., Roman Fleck Executive Chairman of HDAX Therapeutics, and Krisha Panchalingam Director of Lab and Scientific Operations of Portal Innovations, LLC. You can also stop by and see us at exhibition table 3. #RESIBOS #Biotech #RESIBOSTON #preclinicalresearch #preclinical #vcfunding
To view or add a comment, sign in
-
-
Today on the Business of Biotech, molecular biologist-turned-Chief Business Officer Neela Patel and academic-turned-founder of newly-formed Bonum Therapeutics John Mulligan, Ph.D. pull back the curtain on Bonum's transition from its predecessor, Good Therapeutics, Inc., which was fueled by a high-profile asset sale to Roche. Listen in as Neela and John share how the deal got done, how Good turned to Bonum, and where the company's taking its platform next. Listen and subscribe here: https://lnkd.in/edtyEWsF
To view or add a comment, sign in
-
Join Blake Mandell from Transcend Therapeutics at the upcoming Fierce Biotech Summit on Sept 30 - Oct 1 in Boston as he shares his expertise in groundbreaking biotech innovations and advancements. Register now and save up to $500 with the Early Bird Rate: https://ow.ly/uTAE50SyYgy Learn, Network and Connect over two jam-packed days with 500+ industry leaders and gain valuable insights into the future landscape of biotech. Stay Updated on all our events by following Fierce Life Sciences Events #FierceBiotechSummit #WeAreFierce #FierceBiotech #FierceBiotechSummit #BiotechInnovation #LifeSciences #PharmaIndustry #BiotechLeaders #Biotech2024 #BiotechTrends
To view or add a comment, sign in
-
-
🔬 Exciting insights from Labiotech.eu on the top 10 pharma and biotech venture capital arms! These VC arms are driving innovation by investing in transformative therapeutics and cutting-edge technologies. Highlights include AbbVie Ventures' focus on oncology and neuroscience, JJDC's broad pharmaceutical and medtech investments, and Leaps by Bayer's mission to tackle global challenges. Other key players like Pfizer Ventures and Novartis Venture Fund are also making significant contributions to the biotech ecosystem. Read more to discover how these firms are shaping the future of healthcare and biotechnology: https://lnkd.in/eBF5Xx8w 🚀💡
Labiotech.eu
labiotech.eu
To view or add a comment, sign in
-
🏥 Akiram Therapeutics: The transition from lab to market We are happy to see Akiram Therapeutics, one of our portfolio companies, featured in Life Science Sweden. The article explores the significant journey undertaken by Marika Nestor, CEO at Akiram, along with her team, who navigated the path from academia at Uppsala University to an established biotech company. This transition, which involved translating research into a viable commercial entity, underscores the challenges and triumphs of moving from lab bench to patient bedside. With Akiram, we see the critical steps of securing funding and navigating patent landscapes to produce novel treatments for clinical trials. Find the full feature (in Swedish) here: https://lnkd.in/dYtCZqtw At Sciety, this is what we do. We invest in life science and health tech companies like Akiram, that have the potential to make a real difference in people's lives. We are a long-term partner supporting the growth of our portfolio companies, whether it be through introductions to potential customers, partners and team members, or operational and strategic advice. Want to learn more about how we work and what we invest in? Visit our website: https://lnkd.in/dQMctGqm #Sciety #VentureCapital #LifeScience
To view or add a comment, sign in
-
-
Uncover the Secrets of Biotech IT Evolution: Dive into the 'Calculus of IT' with Nathan McBride of Xilio Therapeutics, Inc. As the biotech industry surges forward, it is imperative to grasp the fundamental elements that define success. From do's and don'ts that can make or break a biotech's journey to finely-tuned launchpad strategies tailored for emerging players in the field, Nate delves into it all in our on-demand video. Watch the whole video here: bit.ly/44oJkq8 For more videos from our Life Sciences Summit, visit: bit.ly/3QwcFeU #LifeSciences #Biotech #ClinicalTrials
Egnyte Life Sciences Summit: The Calculus of IT
To view or add a comment, sign in
-
Not long after the official divestment of GRAIL, Illumina have now officially acquired single cell multi-omics player Fluent BioSciences Inc.! We feel Illumina are telegraphing their intentions to increase dominance within the growing single cell multi-omics sector, which is poised to hit a market value of$𝟯𝟱 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 𝗯𝘆 𝟮𝟬𝟯𝟯 👀📈 We wish both Illumina & Fluent BioSciences Inc. the utmost success 🫱🏽🫲🏼 #acquistion #multiomics #masonhardingnews
To view or add a comment, sign in
-
-
With registration in full swing, we want to take a moment to highlight our case company and key sponsors! We will be showcasing each company throughout the registration period, so follow to learn more about these amazing organizations. As a reminder, case teams must complete an application here by Nov. 27 to register! Application here: https://lnkd.in/eyv49w3d Today, we are highlighting our case company, Orange Grove Bio ! Orange Grove Bio’s mission is to positively transform the quality of life of patients with cancer, autoimmune, and inflammatory diseases, by expediting the development of new medical breakthroughs. They strive to foster a more patient-centric approach to drug development and curative therapies through a collaborative ecosystem that bridges early-stage research and pharmaceutical companies. Orange Grove Bio’s Chief Executive Officer and Co-Founder, Marc Appel was an entrepreneur-in-residence at Yale University. In this role, Marc drove the initiative that propelled university intellectual property into the hands of startups to further fuel the New Haven innovation ecosystem. Orange Grove Bio focuses on geographies outside prime venture capital hubs, including the Southeast, Midwest, and Mid-Atlantic. Sourcing throughout these regions aids in accelerating drug development of valuable therapeutics that receive billions of dollars in annual NIH funding, which are more distant from traditional venture capital regions. #innovation #biotech #YHSI2024 #casecompetition
To view or add a comment, sign in
-
-
Join Laia Pascual Ponce (Ship2B Ventures), Fabrizio Conicella (Chiesi USA, Inc.), Salvatore Cappadona (Criteria Bio Ventures), Anna Bellmunt (Asabys Partners), Kerstin Papenfuss, PhD MBA, (Deep Science Ventures) and Alejo Chorny, (AdBio partners) at RESI Europe 2024, June 17-19, a hybrid conference, in-person (June 17), and online partnering (June 18-19), for the Early Stage Therapeutics Panel. The moderator will guide the discussion through topics including how the investors source and vet novel therapeutic assets, what kinds of technology are of interest to them right now, and how they as investors work with a startup to move a new drug toward commercialization. Register: https://lnkd.in/dhxge-zb #RESI #RESIEUROPE #RESIBARCELONA Biocat, BioRegion of Catalonia Biotechgate
To view or add a comment, sign in
-
-
Can it be Done? Making Life Sciences Start-up Transactions Easier and Faster Workshop at #LESAM23! Get the latest template agreement that could speed up negotiations between universities and investors in this informative workshop. Speakers: Katharine Ku (Wilson Sonsini), Rick Brandon (University of Michigan), Galya Blachman (Enliven Therapeutics), Miranda Biven (Wilson Sonsini Goodrich & Rosati)
To view or add a comment, sign in
-